Related Experiment Videos
Pharmacokinetics of clindamycin phosphate in the first year of life
Insights
Intravenous clindamycin phosphate dosing in infants requires age and weight adjustments. Premature infants under 4 weeks need a reduced dose compared to older infants for optimal clindamycin therapy.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Clinical Pharmacy
Background:
- Clindamycin phosphate is an antibiotic used for serious infections.
- Infant pharmacokinetics, particularly in neonates, can differ significantly from adults.
- Understanding clindamycin pharmacokinetics in infants is crucial for safe and effective dosing.
Purpose of the Study:
- To investigate the pharmacokinetics of intravenous clindamycin phosphate in infants under one year of age.
- To determine appropriate dosing recommendations for different infant age and weight groups.
- To compare clindamycin serum concentrations, half-life, and clearance in various infant subpopulations.
Main Methods:
- A pharmacokinetic study involving 40 children under 1 year of age.
- Intravenous administration of clindamycin phosphate.
- Measurement of serum peak and trough concentrations, half-life, and clearance.
Main Results:
- Premature infants (<4 weeks) had a longer serum half-life (8.68 hours) and decreased clearance (0.294 L/hr) compared to term infants.
- Term infants (<4 weeks) showed higher peak concentrations (12.69 µg/ml) than term infants (>4 weeks).
- Infants >3.5 kg exhibited greater clearance (1.919 L/hr) and shorter half-life (1.75 hours) than smaller infants.
Conclusions:
- Recommended intravenous clindamycin dosage is 20 mg/kg/day divided into four doses for infants >4 weeks or >3.5 kg.
- A reduced dose of 15 mg/kg/day in three divided doses is recommended for premature neonates (<4 weeks).
- Term infants >1 week of age can receive the standard 20 mg/kg/day dosage.
Abstract:
The pharmacokinetics of intravenously administered clindamycin phosphate was studied in 40 children less than 1 year of age. Mean peak serum concentrations were 10.92 micrograms/ml in premature infants less than 4 weeks of age, 10.45 micrograms/ml in term infants greater than 4 weeks, and 12.69 micrograms/ml in term infants less than 4 weeks of age. Mean trough concentrations were 5.52, 2.8, and 3.03 micrograms/ml, respectively, in the same groups. Serum half-life was significantly longer (8.68 vs 3.60 hours) in premature compared with term infants less than 4 weeks of age. Both premature and term infants less than 4 weeks had significantly decreased clearance when compared with infants greater than 4 weeks (0.294 and 0.678, respectively, vs 1.58 L/hr). Clearance was significantly greater (1.919 vs 0.310 L/hr) and serum half-life less (1.75 vs 7.57 hours) in infants with body weight greater than 3.5 kg. On the basis of these data it is recommended that in infants greater than 4 weeks or greater than 3.5 kg, intravenous clindamycin dosage be 20 mg/kg/day in four divided doses. In premature neonates less than 4 weeks, the dose should be reduced to 15 mg/kg/day in three divided doses. Term infants greater than 1 week of age may also receive 20 mg/kg/day in four doses.